A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-expressing Tumors
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Amatuximab (Primary)
- Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Morphotek
- 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.